Sunday , October 22 2017

daveIt has been a few years since Dr. Steven Nissan shook the diabetes world apart with his scathing review of the TZDs, pioglitazone and rosiglitizone. Many professionals blame him for the demise of rosiglitizone and the almost-death of pioglitazone, because of his comments on heart problems caused by the class ( http://www.diabetesincontrol.com/letter-from-the-editor-705-avandia-and-fda-approvals/ ). In addition his allegations caused the FDA to require much more cardiovascular testing on all new diabetes medications, pushing their approvals further behind. 2 years after all that clamor, the FDA basically told us that “oops” we were wrong about the TZDs, and the heart problems that supposedly came along with the whole class.

In fact, the newer data points to the cardio-protective value of pioglitazone. This week in our homerun slides specifically designed for Cardiologists, we discuss the use of pioglitazone for diabetes and good heart health.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief